IL301762A - Methods and materials for the treatment of eye diseases - Google Patents

Methods and materials for the treatment of eye diseases

Info

Publication number
IL301762A
IL301762A IL301762A IL30176223A IL301762A IL 301762 A IL301762 A IL 301762A IL 301762 A IL301762 A IL 301762A IL 30176223 A IL30176223 A IL 30176223A IL 301762 A IL301762 A IL 301762A
Authority
IL
Israel
Prior art keywords
antibody
seq
sequence
cdr2
cdr3
Prior art date
Application number
IL301762A
Other languages
English (en)
Hebrew (he)
Original Assignee
Line 6 Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020903624A external-priority patent/AU2020903624A0/en
Application filed by Line 6 Biotechnology Inc filed Critical Line 6 Biotechnology Inc
Publication of IL301762A publication Critical patent/IL301762A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL301762A 2020-10-07 2021-10-07 Methods and materials for the treatment of eye diseases IL301762A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020903624A AU2020903624A0 (en) 2020-10-07 Methods and agents for the treatment of ocular disease
PCT/AU2021/051173 WO2022073072A1 (en) 2020-10-07 2021-10-07 Methods and agents for the treatment of ocular disease

Publications (1)

Publication Number Publication Date
IL301762A true IL301762A (en) 2023-05-01

Family

ID=81127099

Family Applications (1)

Application Number Title Priority Date Filing Date
IL301762A IL301762A (en) 2020-10-07 2021-10-07 Methods and materials for the treatment of eye diseases

Country Status (8)

Country Link
US (3) US11618782B2 (https=)
EP (1) EP4225796A4 (https=)
JP (1) JP2023545579A (https=)
KR (1) KR20230086713A (https=)
CN (1) CN116710135A (https=)
AU (1) AU2021356298A1 (https=)
IL (1) IL301762A (https=)
WO (1) WO2022073072A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
AU2021356298A1 (en) 2020-10-07 2023-05-04 Line 6 Biotechnology, Inc Methods and agents for the treatment of ocular disease
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820858A (en) 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
AU2001290315A1 (en) 2000-11-22 2002-06-03 Mochida Pharmaceutical Co., Ltd. Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
WO2006063292A1 (en) * 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
US20060257411A1 (en) * 2005-05-06 2006-11-16 Bruce Beutler Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway
WO2009002790A2 (en) * 2007-06-26 2008-12-31 Bausch & Lomb Incorporated Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye
WO2009089401A2 (en) * 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for treating or controlling ocular allergy using same
PT3065761T (pt) * 2013-11-05 2020-02-21 Allergan Inc Método de tratamento de condições oculares com um darpin anti-vegf
AU2014370404A1 (en) * 2013-12-24 2016-07-07 Novelmed Therapeutics, Inc. Compositions and methods of treating ocular diseases
EP2898896A1 (en) * 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
US20160038589A1 (en) * 2014-08-11 2016-02-11 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
US10407510B2 (en) * 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
IL309046B2 (en) * 2017-04-21 2025-03-01 Implicit Bioscience Ltd CD14 antagonist antibodies for the treatment of neurodegenerative diseases
KR20190059164A (ko) * 2017-11-22 2019-05-30 건국대학교 글로컬산학협력단 가용성 cd14의 당뇨황반부종 진단 및 치료 용도
AU2021356298A1 (en) 2020-10-07 2023-05-04 Line 6 Biotechnology, Inc Methods and agents for the treatment of ocular disease

Also Published As

Publication number Publication date
AU2021356298A1 (en) 2023-05-04
JP2023545579A (ja) 2023-10-30
US20220220194A1 (en) 2022-07-14
CN116710135A (zh) 2023-09-05
AU2021356298A9 (en) 2024-04-18
US20240002489A1 (en) 2024-01-04
US12258390B2 (en) 2025-03-25
KR20230086713A (ko) 2023-06-15
WO2022073072A1 (en) 2022-04-14
US11618782B2 (en) 2023-04-04
EP4225796A4 (en) 2024-11-13
US20250230228A1 (en) 2025-07-17
EP4225796A1 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
US12258390B2 (en) Methods and agents for the treatment of ocular disease
TWI419704B (zh) 預防及治療與補體相關之眼部病症
JP2020040965A (ja) 補体成分ｃ５抗体
CN107106681B (zh) 治疗或预防中风的方法
JP7760626B2 (ja) 治療に使用するための抗ソルチリン抗体
US20110110932A1 (en) Combination treatment for ocular diseases
TW201720843A (zh) 用於治療纖維化及／或纖維化病症之抗－αＶ整合素抗體
JP2018530574A (ja) 患者の加齢黄斑変性を治療する方法
WO2022011323A1 (en) Ocular disease treatment using anti-tissue factor antibodies
JPWO2018070390A1 (ja) 抗ｒｏｂｏ４抗体と他剤を含む組成物
JP2024508736A (ja) 補体ｃ３抗原結合タンパク質
RU2549700C1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ TNFα
JP2023551734A (ja) 眼の疾患を治療するための組成物及び方法
US20250276059A1 (en) Therapeutic methods and agents for the treatment of myocardial infarction
US20250296996A1 (en) Angiopoietin-related protein 7-specific antibodies and uses thereof
KR20250093319A (ko) Il-6 길항제에 대한 반응 예측
HK40121389A (zh) 预测对il-6拮抗剂的反应